Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeted Next-Generation Sequencing in Succinate Dehydrogenase-Deficient GI Stromal Tumor Identifies Actionable Alterations in the PI3K/mTOR Pathway.
Cicala CM, Matito J, Quindos M, Gómez-Peregrina D, Romero-Lozano P, Fernández-Suárez P, Valverde C, González M, Landolfi S, Pérez-Albert P, Gros L, Vivancos A, Serrano C. Cicala CM, et al. Among authors: gomez peregrina d. JCO Precis Oncol. 2025 Jan;9:e2400497. doi: 10.1200/PO-24-00497. Epub 2025 Jan 9. JCO Precis Oncol. 2025. PMID: 39787462
Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib.
Serrano C, Bauer S, Gómez-Peregrina D, Kang YK, Jones RL, Rutkowski P, Mir O, Heinrich MC, Tap WD, Newberry K, Grassian A, Shi H, Bialick S, Schöffski P, Pantaleo MA, von Mehren M, Trent JC, George S. Serrano C, et al. Among authors: gomez peregrina d. Ann Oncol. 2023 Jul;34(7):615-625. doi: 10.1016/j.annonc.2023.04.006. Epub 2023 Apr 25. Ann Oncol. 2023. PMID: 37105265 Free PMC article. Clinical Trial.
E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor.
García-Valverde A, Rosell J, Sayols S, Gómez-Peregrina D, Pilco-Janeta DF, Olivares-Rivas I, de Álava E, Maurel J, Rubió-Casadevall J, Esteve A, Gut M, Valverde C, Barretina J, Carles J, Demetri GD, Fletcher JA, Arribas J, Serrano C. García-Valverde A, et al. Among authors: gomez peregrina d. Oncogene. 2021 Dec;40(48):6614-6626. doi: 10.1038/s41388-021-02049-0. Epub 2021 Oct 7. Oncogene. 2021. PMID: 34621020
Emerging drugs for the treatment of gastrointestinal stromal tumors.
Pilco-Janeta DF, García-Valverde A, Gomez-Peregrina D, Serrano C. Pilco-Janeta DF, et al. Among authors: gomez peregrina d. Expert Opin Emerg Drugs. 2021 Mar;26(1):53-62. doi: 10.1080/14728214.2021.1896704. Epub 2021 Mar 10. Expert Opin Emerg Drugs. 2021. PMID: 33645383 Review.